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Abstract
Transforming growth factor b (TGF-b) is a powerful promoter of cancer progression and a key target for antitumor therapy.
As cancer cells exhibit active cholesterol metabolism, high density lipoproteins (HDLs) appear as an attractive delivery
system for anticancer TGFb-inhibitory molecules. We constructed a plasmid encoding a potent TGF-b-blocking peptide
(P144) linked to apolipoprotein A-I (ApoA-I) through a flexible linker (pApoLinkerP144). The ApoLinkerP144 sequence was
then incorporated into a hepatotropic adeno-associated vector (AAVApoLinkerP144). The aim was to induce hepatocytes to
produce HDLs containing a modified ApoA-I capable of blocking TGF-b. We observed that transduction of the murine liver
with pApoLinkerP144 led to the appearance of a fraction of circulating HDL containing the fusion protein. These HDLs were
able to attenuate TGF-b signaling in the liver and to enhance IL-12 -mediated IFN-c production. Treatment of liver
metastasis of MC38 colorectal cancer with AAVApoLinkerP144 resulted in a significant reduction of tumor growth and
enhanced expression of IFN-c and GM-CSF in cancerous tissue. ApoLinkerP144 also delayed MC38 liver metastasis in Rag22/
2IL2rc2/2 immunodeficient mice. This effect was associated with downregulation of TGF-b target genes essential for
metastatic niche conditioning. Finally, in a subset of ret transgenic mice, a model of aggressive spontaneous metastatic
melanoma, AAVApoLinkerP144 delayed tumor growth in association with increased CD8+ T cell numbers in regional lymph
nodes. In conclusion, modification of HDLs to transport TGF-b-blocking molecules is a novel and promising approach to
inhibit the growth of liver metastases by immunological and non-immunological mechanisms.
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Introduction
Transforming growth factor b (TGF-b) has long been recog-
nized as a key promoter of tumor growth and a critical initiator of
the metastatic process [1]. Most established tumors develop
mutations in the TGF-b-signaling pathway. These mutations
confer the tumor cells the possibility of bypassing TGF-b–
mediated growth inhibition while making use of the ability of this
cytokine to enhance tumor growth, invasion, and metastasis [2].
TGF-b is a potent inducer of epithelial-mesenchymal transition
(EMT) [3], a process by which tumor cells lose epithelial
characteristics and acquire enhanced migratory and invasive
capabilities. Moreover, TGF-b directly promotes the expression of
key angiogenic factors such as VEGF [4] and induces metallo-
proteases like MMP9 [5], facilitating tumor vascularization and
matrix remodeling which are critical events involved in condi-
tioning the metastatic niche [6]. TGF-b also stimulates tumor
invasion and metastasis by inhibiting anti-tumor immune surveil-
lance and promoting local immune suppression. Along this line,
TGF-b directly inhibits NK and T cell proliferation and
suppresses CD8+ T cell cytotoxicity by transcriptional repression
of genes encoding perforin, granzymes and cytotoxins [7]. In
addition, TGF-b induces FoxP3 thereby generating inducible
regulatory T lymphocytes and exerts additional immunosuppres-
sive functions by acting on myeloid-derived suppressor cells,
tumor-associated neutrophils and tumor-associated macrophages
[1,7]. Thus, TGF-b is a polyvalent cytokine that favors tumor
growth and spread by a diversity of mechanisms. Accordingly,
antitumor strategies directed to effectively block TGF-b have long
been sought. However, attempts to antagonize TGF-b in
malignant processes were not followed by clear clinical benefit
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and clinical development of two of the three products which
reached phase II were discontinued [8].
We have previously reported that a lipophilic 14-mer peptide
derived for type III TGF-b receptor, termed P144, is a potent
TGF-b inhibitor that displays therapeutic effects in models of liver
fibrosis [9], scleroderma [10] and myocardial fibrosis [11]. In the
present work, we tested the effect of P144 in animal models of
metastatic liver cancer. To ensure sustained serum levels of the
bioactive molecule, we used a liver-directed gene therapy
approach employing adeno-associated viral vectors (AAV) which
enable long-term expression of the transgene. As tumors exhibit an
active cholesterol metabolism and express high levels of the ApoA-
I receptor, SRB1 [12,13], we constructed a transgene formed by
p144 fused to ApoA-I through a flexible linker (ApoLinkerP144).
Consonant with the fact that ApoA-I is the main protein of HDLs,
here we show that transduction of the liver with a vector encoding
ApoLinkerP144 leads to the secretion of HDLs with TGF-b
blocking properties and that this strategy is an efficient therapy to
inhibit the growth of liver tumor metastases.
Materials and Methods
Cell lines
MT\Ret melanoma was described in [14]. MC38 is a colon
adenocarcinoma cell line of C57BL/6 origin whose identity has
been verified by Idexx Radil (Columbia, MO, USA. Case 6592–
2012) and was provided to us by Dr. Karl E. Hellstro¨m (Seattle,
WA) [15]. Mv-1-Lu lung carcinoma (ATCC CCL-64) and mouse
colon carcinoma cell lines CT26 (ATCC CRL-2638) were
obtained from American Type Culture Collection (Manassas,
VA, USA). Cells were maintained in RPMI 1640 with or without
GlutaMAX respectively and supplemented with 10% heat-
inactivated fetal calf serum, 100 units/ml penicillin, 100 mg/ml
streptomycin and 561025 mol/l 2-mercaptoethanol (RPMI com-
plete medium).
Ethics Statement
This study was carried out in strict accordance with the
institutional guidelines for animal care of the University of
Navarra and German Cancer Research Center (DKFZ). The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of Navarra and by the Committee
on the Ethics of Animal Experiments of the German Cancer
Research Center (DKFZ) (experiment with ret mice). All surgery
was performed under isofluorane anesthesia, and all efforts were
made to minimize suffering. Mice were sacrificed by CO2
inhalation.
Mice
Five to seven-week-old female BALB/c and C57BL/6 mice
(Harlan Laboratories, Barcelona, Spain), Rag22/2IL2rc2/2 and
ApoA-I2/2 mice were kept in the University of Navarra animal
facilities and cared for according to the institutional guidelines for
animal care. C57BL/6 mice expressing human ret oncogene in
Figure 1. Blockade of TGF-b in vivo by ApoLinkerP144 delivered either by gene therapy or bound to HDL. (A) Western blot against
ApoA-I with purified HDL fractions of plasma obtained from animals which received 24 h before either pApo or pApoLinkerP144 by hydrodynamic
injection. (B) Inhibition of TGF-b by HDL from mice injected with Apo plasmid (HDL Apo) or HDL containing ApoLinkerP144 (HDL ApoLinkerP144)
measured using Mv-1-Lu cells cultured in the presence of 200 pg/ml of TGF-b and 10 mg/ml HDLs. Mean6SEM *, P,0.05 (C) Strengthened pStat-1
expression and diminished pSmad-2 expression in livers from mice which received IL-12 plasmid and HDL Apo or HDL ApoLinkerP144. Numbers
indicate the relative intensity of the bands. (D) IFN-c production 4 days after IL-12 plasmid hydrodynamic injection combined with i.p injection of
HDL Apo or HDL ApoLinkerP144 or a hydrodynamic injection of pApoLinkerP144 in C57BL/6 mice (n= 4 mice/group). Mean6SEM **, P,0.01.
doi:10.1371/journal.pone.0096799.g001
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melanocytes were provided by I. Nakashima (Chubu University,
Aichi, Japan) and experiments were performed in accordance with
German government and DKFZ institutional guidelines and
regulations.
Animal manipulation
Hydrodynamic administration of plasmids was performed with
20 mg purified plasmids prepared with EndoFree Maxi Kit
(Qiagen, Valencia, CA). IL-12 was expressed under the control
of a liver-specific Dox-inducible system. Doxycycline (Sigma,
Madrid, Spain) was given to IL-12 treated animals at a
concentration of 2 mg/ml in drinking water containing 5%
sucrose (Panreac, Barcelona, Spain). Blood samples were obtained
by retro-orbital bleeding and serum was obtained and stored at –
20uC until assayed.
For the model of colorectal metastasis in the liver, 56105 MC38
cells were inoculated in the spleen after laparotomy. Once mice
recovered from anesthesia, AAV vectors were inoculated in 200 ml
saline by intraperitoneal injection. Rag22/2IL2rc2/2 mice were
sacrificed at day 10 and C57BL/6 at day 15. Tumor area in
images of the livers was measured quantifying the pixels over a
threshold color using Matlab software (Matworks, Natick, MA,
USA). Samples from healthy liver and tumors were stored at 2
80uC until assayed.
5 week-old Ret transgenic tumor-bearing mice received either
saline or AAVApoLinkerP144 by intraperitoneal injection. Both
groups were monitored daily for tumor progression to assess
survival. In a set of experiments, remaining mice were sacrificed at
day 50 upon treatment. Responder and non-responder classifica-
tion of AAVApoLinkerP144–treated mice was done post-hoc
regarding tumor weight. Fresh tumor and lymph node samples
were mechanically dissociated in ice-cold PBS and filtered through
cell strainers (BD Biosciences, San Jose, CA, USA). Samples were
depleted of erythrocytes by ammonium chloride lysis, washed
twice and stored on ice.
CD3 and pAKT immunostaining
For CD3 quantification, liver samples containing tumor nodules
were embedded in Tissue-Tek OCT (Sakura, Zoeterwoude, The
Netherlands). Samples were air dried, and fixed in 4% formalde-
hyde for 5 min. Endogenous peroxidase was quenched with 3%
H2O2 in methanol for 10 min. Tissue sections were incubated o/n
at 4uC with anti-human CD3 (clone SP7, Lab Vision Corporation,
Fremont, CA) diluted 1:100 in TBS. Then, sections were
incubated with anti-rabbit EnVision HRP-polymer (Dako, Car-
pinteria, CA) and revealed using DAB+ (Dako). Sections were
lightly counterstained with Harris hematoxilin. For pAKT
evaluation, formalin-fixed paraffin-embedded liver sections
(3 mm thick) were dewaxed and hydrated. Antigen retrieval was
performed for 30 min at 95uC in 0,01 M Tris-1 mM EDTA
(pH=9) in a Pascal pressure chamber (S2800, Dako). Endogenous
peroxidase was blocked with 3% H2O2 in deionized water.
Sections were incubated overnight at 4uC with anti-phosphoAKT
(1:50, Cell Signaling, 4060). After rinsing in TBS-T, the sections
were incubated with goat anti-rabbit EnVision (Dako; Glostrup,
Denmark) for 30 min and peroxidase activity was revealed using
DAB+ (Dako). Finally, sections were lightly counterstained with
Harris hematoxylin, dehydrated, and coverslipped.
Antibodies and flow cytometry
Rabbit anti phospho-Smad2 (Millipore, Billerica, MA, USA),
rabbit anti Smad2/3 (Cell Signaling Technology, Danvers, MA,
USA), rabbit anti phospho-Smad3 (Cell Signaling Technology),
goat anti phospho-Smad1/5/8 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), rabbit anti Smad1/5/8 (Santa Cruz Biotech-
nology), rabbit anti-mouse phospho-Stat1 (Cell Signaling Tech-
nology), rabbit anti-mouse ApoA-I (Santa Cruz Biotechnology),
rabbit anti-mouse Actin (Sigma, Steinheim, Germany) and HRP
conjugate donkey anti-rabbit IgG (Southern Biotech, Birmingham,
AL, USA) were used for western blot analysis. Rabbit anti SRB1
monoclonal antibody (Novus Biologicals, CO, USA) and FITC
conjugated anti-rabbit IgG (Sigma, Steinheim, Germany) were
used for flow cytometry analysis. Fc block and fluorochrome
conjugated antibodies against mouse CD45, CD3, CD8, MHC-II,
CD11c and TNF-alpha were purchased from BD Biosciences.
Intracellular staining for TNF-alpha was performed following
manufacturer’s instructions. For flow cytometry experiments
acquisition was done using either FACSCalibur or FACSCanto
II (BD Biosciences). FlowJo Software (TreeStar) was used to
analyze cellular events.
Plasmids
pIL-12 and pApo have been previously described [16,17]. To
obtain the plasmid pApoLinkerP144, we used the plasmid
pCMV-mApoA-IAscI [16] digested with AscI and NotI.
FwLinkerP144 and RvLinkerP144 primers were then hybridized,
leaving cohesive ends that match with AscI excision site in 59 and
NotI in 39. This primer introduced a flexible linker sequence
derived from pyruvate ferredoxin oxidoreductase between ApoA-
I and P144. The plasmid pSpP144, with the signal peptide of
ApoA-I followed by the coding sequence of P144, was obtained
by PCR with primers FwATGmApoA-I and RvSPmApoAIP144
and as a template, pCMV-mApoA-IAscI. Primers are listed in
Table S1.
Adeno-associated virus (AAV) production
All AAV plasmids contain an expression cassette flanked by two
inverted terminal repeats from the AAV2. The expression cassette
contains the ubiquitous human 1-a elongation factor (EF1-a)
promoter, the gene encoding for mouse ApoA-I (apoa1, Gen-
eID:11806) or the cDNA encoding for ApoLinkerP144 and the
bovine growth hormone polyadenylation sequence [bGH poly(A)]
(bases 2,326–2,533: GenBank accession no. M57764). AAV2/8
vectors were produced by calcium phosphate–mediated transfec-
tion of HEK-293T cells. The resulting viral vectors (AAVApo or
AAVApoLinkerP144) were harvested and purified by iodixanol-
gradient centrifugation followed by filtration and further concen-
tration against phosphate- buffered saline–5% sacarose. Viral
titers in terms of genome copies per milliliter (gc/ml) were
determined by quantitative polymerase chain reaction.
qRT-PCR
Total RNA either from mice livers or from liver tumor nodules
was isolated using TRI reagent (Sigma, Dorset, UK). RNA was
treated with DNase I and retrotranscribed to cDNA with MMLV
RT in the presence of RNase OUT (all reagents from Invitrogen,
Carlsbad, CA, USA) according to manufacturer’s instructions.
Primers for quantitative real time RT-PCR are listed in Table S1
in File S1. H3F3 histone was used to standardize gene expression.
The mRNA values were represented by the formula 2DCt, where
DCt indicates the difference in the threshold cycle between H3F3
histone and the target genes (all reagents from BioRad, Hercules,
CA, USA).
Reagents
Peptide SPSYVYHQF (hereafter AH1) is a cytotoxic T cell
determinant expressed by CT26 cells and presented by H-2Ld
Antitumor Activity of ApoLinkerP144
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MHC class I molecules was purchased from Proimmune Ltd.
(Oxford, United Kingdom). IL-12p70, interferon gamma (both
BD Biosciences) and mouse ApoA-I (Cusabio Biotech Ltd.) serum
levels were quantified by ELISA kits according to manufacturer’s
instructions. Peptide P144 (TSLDASIIWAMMQN) was obtained
from Digna Biotech (Madrid, Spain). Recombinant ApoLin-
kerP144 was produced and purified by Genscript (Piscataway, NJ,
USA).
HDL isolation by sodium bromide gradient differential
ultracentrifugation
24 hours after hydrodynamic delivery of pApo or pApoLin-
kerP144 plasmids, HDL isolation was performed from pool plasma
samples as described by Fioravanti et al. [16].
In vitro assay of the TGF-b blocking activity of HDL using
Mv-1-Lu cells
Mv-1-Lu cells (5000 cells/well) were cultured in a 96-well flat-
bottomed plate (Costar Corporation CA, USA) at 37uC, 5% CO2
overnight in complete medium (RPMI1640 containing L-gluta-
mine and supplemented with 5% fetal calf serum and antibiotics).
HDLs (10 mg/ml) were tested by triplicate in the presence of
200 pg/ml TGFb1 (R&D, Minneapolis, MN). Cell proliferation
after 72 h was determined using ViaLight Plus Kit (Lonza,
Rockland, ME, USA). As positive and negative controls, we used
Mv-1-Lu cells grown in absence or presence of human TGF-b,
respectively. Percentage of inhibition of TGF-b was calculated
normalizing data with the positive and negative controls.
Figure 2. Sustained expression of ApoLinkerP144 in the liver using an AAV vector significantly diminishes the occurrence of
primary liver metastasis. (A) ApoA-I Western blot analysis performed on supernatants of 293T cells producing the AAV vectors. (B) ApoA-I
deficient mice received 461011 genome copies/mice i.v. (n= 6/group) and ApoA-I production in serum was quantified by ELISA. (C) 56105 MC38
colon carcinoma cells were intrasplenically injected. At the same time, 461012 AAVApo or AAVApoLinkerP144 vg/mice were i.p injected (n=6/group).
Mice were sacrificed at day 15 after tumor cell inoculation and tumor area in the liver was measured quantifying the pixels over a threshold color
using Matlab software. Mean6SEM **, P,0.01. (D) IFNc and GM-CSF expression in metastatic nodules in the liver was assessed by RT-PCR.
Mean6SEM *, P,0.05. **, P,0.01 (E) Representative pictures of immunohistochemical staining of CD3 in the metastatic nodules in the liver
(Magnification: 2006) and quantification of CD3+ pixels per field in ten fields per animal quantifying the pixels over a threshold color using Matlab
software (Magnification: 1006). Mean6SEM *, P,0.05.
doi:10.1371/journal.pone.0096799.g002
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Statistical analysis
Prism software (GraphPad Software, Inc.) was employed to
perform statistical analysis. Log-rank test was used to determine
the significance of differences in survival curves and percentage
of tumor-free mice. Differences in other parameters among
groups were analyzed by Student’s T test or with one-way
ANOVA followed either by Dunnett’s or by Bonferroni’s
posttest. P values ,0.05 were considered to be statistically
significant.
Results
Liver transduction with a plasmid encoding the fusion
protein ApoA-I/P144 results in the secretion of HDLs with
TGF-b blocking properties
TGF-b is known to be a key driver of tumor metastases [2]. In
this work, we sought to use P144, a potent anti-TGF-b peptide, to
inhibit the growth of metastatic liver cancer. Since synthetic
peptides have short half-life in the circulation, we tried to solve this
problem by transducing the liver with genetic constructs encoding
P144. Two plasmids were used: one containing P144 bound to a
secretory signal peptide (pSpP144) and another with P144 linked
to ApoA-I through a flexible linker (pApoLinkerP144). In addition,
we employed a plasmid encoding ApoA-I (pApo) to serve as a
control. We decided to fuse P144 to ApoA-I as this molecule is the
main component of high density lipoproteins (HDL) and we have
previously shown that when hepatocytes are compelled to express
a cytokine linked to ApoA-I, the fusion protein circulates in plasma
incorporated into HDLs [16]. We reasoned that conveyance of
P144 by HDLs might favour its antitumor activity as cancer cells
exhibit an active cholesterol metabolism and express high levels of
the ApoA-I receptor, SRB1 [12,13].
In preliminary experiments, we tested the TGF-b inhibitory
activity of the different constructs using an in vivo assay based on
the ability of TGF-b to inhibit interleukin 12 (IL-12)-mediated
interferon-c (IFN-c) production [18]. Thus, we transduced the
liver of BALB/c mice by hydrodynamic co-injection of a plasmid
encoding IL-12 (pIL-12) together with pApo, pSpP144, or
pApoLinkerP144. We found that only pApoLinkerP144 was able
to increase intrahepatic IFN-c expression following liver trans-
duction with pIL-12 (Figure S1A in File S1). We also analyzed the
adjuvant activity of pApo, pSpP144 and pApoLinkerP144 in
prophylactic vaccination of BALB/c mice with the AH-1 peptide
derived from CT26 colon cancer, a setting where TGF-b blockade
has been shown to enhance antitumor immune responses [19]. We
found that after subcutaneous implantation of CT26 cells the
tumor developed in all vaccinated mice treated with pApo or
pSpP144 while those which received pApoLinkerP144 remained
tumor-free (Figure S1B in File S1). Thus, our data showed that
only pApoLinkerP144 exhibited immunostimulatory properties
likely derived from its anti-TGF-b activity. Thus, we continued the
characterization of ApoLinkerP144 using ApoA-I as control.
To see whether ApoLinkerP144 circulated incorporated into
HDLs, mice were treated by hydrodynamic injection with pApo or
pApoLinkerP144 and 24 hours later, the HDL fraction of plasma
was isolated and subjected to Western blot using an anti-ApoA-I
antibody. We observed that mice that received pApoLinkerP144
showed an additional band of higher molecular weight than
ApoA-I likely corresponding to the fusion protein (Figure 1A).
Then, we analyzed whether HDLs from pApoLinkerP144-treated
mice were able to block TGF-b activity in vitro using a bioassay
based on the ability of TGF-b to inhibit the proliferation of the
Mv-1-Lu cells. As shown in Figure 1B, HDLs from pApoLin-
kerP144-treated mice were able to partially restore the prolifer-
ation of Mv-1-Lu cells incubated in the presence of TGF-b.
Moreover, we analyzed the inhibitory activity of a recombinant
ApoLinkerP144 on the TGF-b signaling in MC38 cells. We
observed a reduction in both Smad2 and 3 phosphorylation
(Figure S2 in File S1). To analyze whether HDLs containing
ApoLinkerP144 could block TGF-b in vivo, C57BL/6 mice were
subjected to hydrodynamic injection of pIL-12 and injected
intraperitoneally at the same time with HDLs isolated from mice
that had received pApo or pApoLinkerP144. We found that co-
administration of pIL-12 plus ApoLinkerP144-containing HDLs
was able to attenuate Smad2 phosphorylation while enhancing
Stat1 activation and therefore IFN-c production in serum
(Figure 1C, D). These data show that HDL containing
ApoLinkerP144 attenuates TGF-b signaling and stimulates IFN-
c production within the liver.
An adeno-associated viral vector encoding
ApoLinkerP144 enables sustained in vivo transgene
expression and displays anti-tumor activity in a model of
liver metastasis
We then tested whether sustained expression of ApoLinkerP144
in hepatic tissue could exert antitumor effects in a model of
metastatic colorectal cancer in the liver. To this aim, we selected a
recombinant AAV vector to express ApoA-I or ApoLinkerP144 in
the liver as these vectors allow long term transgene expression and
have already been used in humans with good tolerance [20]. We
employed AAV serotype 8 because among all serotypes this is the
one with the highest liver transduction efficiency in mice [21].
Thus, we produced AAV vectors encoding ApoA-I (AAVApo) or
ApoLinkerP144 (AAVApoLinkerP144) and the expression of these
molecules was verified by Western blot analysis in supernatants of
293T-HEK cells transfected with the plasmids used to generate the
respective vectors (Figure 2A). Next, AAVApo or AAVApoLin-
kerP144 at the dose of 461012 vg/mice were injected intrave-
nously in ApoA-I deficient mice and serum ApoA-I was
quantitated by ELISA at different time points. We observed that
with either of the two vectors serum levels of the transgene were
maintained at values above 4 mg/ml during at least one month
(Figure 2B).
Then, we studied whether AAVApoLinkerP144 could affect the
growth of metastatic lesions in the liver of C57BL/6 mice
following intrasplenic injection of 56105 MC38 colon cancer cells.
This tumor cell line was chosen as it is representative of SRB1
expressing tumors (Figure S3 in File S1). After administration of
the neoplastic cells, the animals received AAVApoLinkerP144
(461012 vg/mice) or the same dose of AAVApo by intraperitoneal
injection. We observed a significant reduction of MC38 metastatic
lesions in mice treated with AAVApoLinkerP144 compared to
those given AAVApo (Figure 2C). A similar antitumor effect was
observed after administration of 200 mg P144 in carbonate buffer
(pH 9.5) every day, indicating that AAVApoLinkerP144 was an
efficient delivery vehicle of the anti-TGFb peptide (Figure S4 in
File S1).
TGF-b plays a key role in cancer progression by suppressing
antitumor immunity but also by inducing tumor cell dediffer-
entiation, EMT and metastatic behavior [22]. Thus, we
explored whether the antitumor effect of AAVApoLinkerP144
was associated with modulation of immune and/or non-immune
processes. We found that immunocompetent mice with hepatic
metastasis of MC38 cancer which received AAVApoLinkerP144
showed enhanced expression of IFN-c and GM-CSF in the
metastatic nodules compared to those treated with AAVApo
(Figure 2D). Indeed, immunohistochemical analysis showed an
Antitumor Activity of ApoLinkerP144
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increase in the number of tumor infiltrating T cells in mice that
received AAVApoLinkerP144 compared to those given AA-
VApo (Figure 2E). In addition, we also observed by immuno-
histochemical analysis a reduction in the phosphorylation of
AKT in the tumor nodules of mice treated with AAVApoLin-
kerP144, reflecting that the fusion protein was able to block a
non-canonical TGF-b signaling pathway in vivo (Figure S5 in
File S1). Then, we analyzed whether AAVApoLinkerP144 could
also inhibit liver metastasis in immunocompromised animals. To
this aim, AAVApo or AAVApoLinkerP144 (461012 vg/mice)
were administered to Rag22/2IL2rc2/2 mice inoculated with
MC38 cells into the spleen (Figure 3A). We found that mice
treated with AAVApoLinkerP144 showed a significant reduction
of tumor burden in the liver suggesting that non-immunological
mechanisms contribute to the antitumor activity of this therapy.
Indeed, different TGFb-target genes including MMP9, COX-2
and FGFR1, which are critical for the conditioning of the
metastatic niche [23,24,25], were significantly dowregulated in
Rag22/2IL2rc2/2 mice treated with AAVApoLinkerP144 com-
pared to those that received AAVApo (Figure 3B). The mRNA
levels of periostin, another TGFb-inducible factor important for
tumor progression [26], tended to be lower in the former group
of animals being the difference at the limit of statistical
significance (p = 0.06) (Figure 3B).
AAVApoLinkerP144 exerts antitumor effects against
spontaneous metastatic melanoma
Having shown that ApoLinkerP144 inhibits liver metastases in a
transplantable tumor model, we investigated the antitumor
potential of ApoLinkerP144 in ret transgenic mice. These animals
spontaneously develop skin malignant melanoma metastasizing to
lymph nodes, lungs, brain, liver and the bone marrow [27,28,29].
This model was chosen since it is representative of a highly
aggressive spontaneous metastatic tumor, and high SRB1 expres-
sion levels were found to be present in cell lines derived from this
malignancy (Figure 4A). Ret transgenic mice received a single dose
of AAV ApoLinkerP144 or PBS (n= 7 per group) and the animals
were followed for survival. In a different experiment, similar
treatments were administered to the transgenic animals which
were then sacrificed at day 21 (n= 7 per group) or 50 (PBS n=7, 5
alive by day 50, treated n= 12, 11 alive). In the first experiment,
all animals in the control group died by day 80 while 40% of those
that received AAVApoLinkerP144 survived at day 100 although
succumbed by day 120 (Figure 4B). In the second experiment, at
day 50 after vector injection, 6 of the treated mice exhibited a liver
tumor burden than tended to be reduced compared with mice
injected with PBS (p= 0.06) while in the other 5 treated mice
tumor progression was similar to controls (Figure 4C). The former
group of 6 mice was designed as the responder group.
Interestingly, responder mice presented a significant increase in
the percentage of CD8+ T lymphocytes in the lymph nodes
(Figure 4D). Moreover, the analysis of dendritic cells infiltrating
the tumors showed that upon an overnight incubation with LPS
(10 ng/ml), the expression of TNF-a was significantly higher in
the responder group than in PBS -treated animals, while no
differences were found between this last group and non-responders
(Figure 4D). These data point to higher stimulation of adaptive
immunity and stronger pro-inflammatory phenotype in antigen
presenting cells of animals treated with AAVApoLinkerP144.
Discussion
TGF-b is a pleiotropic cytokine that acts as a key driver of the
metastatic process [2]. It mediates EMT and is essential for the
preparation of the metastatic niche, for local conditioning of the
extracellular matrix and for suppression of anti-tumor immunity
[30]. It is therefore a relevant target for cancer therapy as its
blockade would promote protective antitumor immune responses
while simultaneously interfering with biological changes that are
crucial for metastases progression [8]. P144 is a synthetic peptide
that has been shown to attenuate liver fibrosis, scleroderma and
miocardial esclerosis in different animal models (9–11). Impor-
tantly, local application of P144 as a cream has already been used
in humans in a phase II clinical trial for skin fibrosis in systemic
sclerosis [8]. Synthetic peptides, however, have very short half-life
Figure 3. Hepatic tumor nodule incidence by ApoLinkerP144 is also diminished in immunodeficient mice by modulating TGF-b–
dependent molecules. (A) 56105 MC38 colon carcinoma cells were intrasplenically injected and 461012 AAVApo or AAVApoLinkerP144 vg/mice
were simultaneously i.p injected in Rag22/2IL2rc2/2 mice (n= 6/group). Mice were sacrificed at day 10 after the tumor cell inoculation and the tumor
area in the liver was measured quantifying the pixels over a threshold color using Matlab software. Mean6SEM *, P,0.05. (B) FGFR1, MMP9, periostin
and COX-2 expression in tumor liver metastases from Rag22/2IL2rc2/2 mice was assessed by RT-PCR. Mean6SEM *, P,0.05.
doi:10.1371/journal.pone.0096799.g003
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in circulation; a feature that limits their use as systemic therapy for
conditions like malignancies. In order to maintain sustained
plasma levels of the peptide, we transduced the liver with different
constructs encoding P144. When using the peptide sequence
bound to a secretory signal peptide, this construct did not
markedly increase the IFN-c induced by IL-12 and did not
increased the immune response against a peptide-based vaccine.
The lack of activity could be due to a defective secretion of the
peptide or inadequate interaction of the secreted molecule with its
target. In contrast, the fusion of P144 to ApoA-I through a flexible
linker (ApoALinkerP144) resulted in the secretion to plasma of a
fraction of HDLs with TGF-b blocking activity. In a previous
report, we showed that the transduction of hepatocytes with a
cytokine like IFN-a linked to ApoA-I caused the release to serum
of the fusion protein incorporated into HDLs. In the present
paper, we show that similarly happens when linking a short
peptide such as P144 to ApoA-I. It should be noted that P144 is
highly lipophilic and it seems possible that its bioavailability in vivo
might be favored by becoming an integral part of lipoproteins.
As mentioned above, the idea of conveying the TGF-b
inhibitor incorporated into HDLs is very attractive as choles-
terol metabolism is essential for sustained cell growth and it is
very active in tumors [12]. A great diversity of tumors,
including colorectal cancer, express high levels of the ApoA-I
receptor SRB1 which mediates the uptake of cholesteryl esters
and other lipids from HDLs [13,31,32]. Indeed, the avidity of
tumor cells for HDLs was soon appreciated and HDL and
ApoA-I decorated particles have been used as drug carriers to
deliver lipophilic drugs to tumors [13,33].
Remarkably, administration of AAVApoLinkerP144 to immu-
nocompetent mice exhibiting liver metastases induced a significant
reduction of tumor burden in association with increased numbers
of infiltrating T cells and upregulation of pro-inflammatory and
immunostimulatory molecules such as GM-CSF and IFN-c. The
inhibition of liver metastasis was also observed in spontaneous
tumors that overexpress SRB1 like the ret transgenic mouse model
of aggressive spontaneous melanoma, which is very difficult to
treat.
Importantly AAVApoLinkerP144 also reduced metastatic
nodules in the liver of Rag22/2IL2rc2/2 mice indicating that
the antineoplastic effects of this vector are not only due to
activation of antitumor immunity but also to interference with
non-immune pro-tumorigenic activities of TGF-b. Indeed, in the
metastatic lesions of these animals, we observed reduced
expression of MMP9, COX-2, periostin and FGFR1. All these
molecules are TGF-b targets and essential factors for tumor
progression [23,24,25]. Therefore, AAVApoLinkerP144 appears
to counteract metastatic tumor growth by way of both immune
and no-immune mechanisms. These multifaceted actions have
previously been described with other TGF-b inhibitors [34,35].
In conclusion, AAVApoLinkerP144 allows the secretion by liver
cells of HDLs with the ability to block TGF-b, representing a
novel approach to combat liver metastasis. This treatment might
prove to be synergistic with other targeted therapies or immuno-
therapies.
Figure 4. Sustained expression of ApoLinkerP144 delays tumor progression and increases intratumoral CD8 T cell infiltration in a
mouse model of spontaneous melanoma. (A) Scavenger Receptor B class 1 (SRB1) expression on two different Ret cell lines (established from
primary skin melanomas) analyzed by flow cytometry. (B) Ret transgenic tumor-bearing mice were injected i.p either with saline or 461012 gc/mouse
of AAVApoLinkerP144 (n= 7/group). Results are displayed as Kaplan-Meier plot of mice survival. Cumulative data of two independent experiments are
shown. (C) Ret transgenic mice were injected i.p either with saline or 461012 gc/mouse of AAVApoLinkerP144. Then, mice were sacrificed either at
day 21 (n= 7/group) or 50 (saline, n= 5; treatment n= 11) after injection. Mice sacrificed at day 50 were classified as responder (R; grey bar, n= 6) or
non-responder (NR; white bar, n= 5) regarding tumor weight; (D) Cells from primary skin tumors and metastatic lymph nodes were isolated at day 50
upon the treatment Frequency of CD8+ T lymphocytes in metastatic lymph nodes and of tumor-infiltrating dendritic cells producing TNF-a upon the
treatment overnight with LPS measured by flow cytometry were presented as a percentage within the respective cell population; Mean6SEM *, P,
0.05.
doi:10.1371/journal.pone.0096799.g004
Antitumor Activity of ApoLinkerP144
PLOS ONE | www.plosone.org 7 May 2014 | Volume 9 | Issue 5 | e96799
Supporting Information
File S1 Contains the following files: Figure S1. In vivo assays to
select the best anti-TGF-b inhibitor. (A) A plasmid encoding IL-12
(pIL-12) was administered to C57BL/6 mice by hydrodynamic
injection together with pApo, pSpP144, or pApoLinkerP144.
Four days later, IFN-c serum levels were quantified by ELISA.
**p,0.01. (B) BALB/c mice were immunized with AH-1 peptide
emulsified in incomplete Freund’s adjuvant. At day 7 after
immunization, mice received plasmids pApoA-I, pSpP144 or
pApoLinkerP144 via hydrodynamic injection. Seven days later,
mice were injected s.c. with 2.56105 CT26 tumor cells. Results
are displayed as Kaplan-Meier plot of tumor occurrence.
Treatment groups were compared using the log-rank test. Data
are representative of one of two independent experiments (n = 6
mice/group). *p,0.05.**p,0.01. Figure S2. Inhibitory effect of
ApoLinkerpP144 on TGF-b signaling. 56105 MC38 cells were
plated in a 6-well plates. After an overnight incubation, cells were
left untreated or treated with 100 pM TGF-b with or without
100 mg/ml rApoLinkerP144. 60 minutes later, cells were harvest-
ed and Western blot analysis was performed to determine the
phosphorylation status of Smad2, Smad3 and Smad1/5/8.
Figure S3. Scavenger receptor class B type I (SRB1) expression
on MC38 tumor cell line. 36105 tumor cells were cultured in 6-
well plates for 48 hours. Then, cells were harvested and stained to
show SRB1 surface expression by flow cytometry analysis.
Expression was compared with isotype control. Data are
representative of two independent experiments. Figure S4.
Antitumor efficacy of P144. 56105 MC38 colon carcinoma cells
were intrasplenically injected. The same day, we started a daily
treatment with vehicle (carbonate buffer pH 9.5) or 200 mg P144
in carbonate buffer (pH 9,5) for 15 days (n = 6/group). Mice were
sacrificed at day 15 after tumor cell inoculation and tumor area in
the liver was measured quantifying the pixels over a threshold
color using Matlab software. Mean6SEM *, P,0.05. Figure S5.
Immunohistochemical staining of pAKT in the metastatic nodules
in the liver. 56105 MC38 colon carcinoma cells were intrasplen-
ically injected. At the same time, 461012 AAVApo or AAVApo-
LinkerP144 vg/mice were i.p injected (n= 6/group). Mice were
sacrificed at day 15 after tumor cell inoculation and liver were
fixed with formalin and embedded in paraffin. Immunhistochem-
ical staining of pAKT was performed. A representative picture of
pAKT in the metastatic nodules in the liver is shown (Magnifi-
cation: 1006). Table S1. Primers designed to clone the different
peptide fusions and the primers used for quantitative PCR
analysis.
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